fa Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma پاتولوزی دهان، فک و صورت Oral and Maxillofacial Pathology پژوهشي Research <p> <strong>Objectives</strong></p><p>  To evaluate the expression of phosphorylated mammalian target of rapamycin (p-mTOR) and phosphatase and tensin homolog deleted on chromosome TEN (PTEN) in oral squamous cell carcinomas (OSCCs) and relate them with clinicopathologic characteristics and outcome. <strong></strong></p><p> <strong>Study Design</strong></p><p>  We analyzed p-mTOR and PTEN protein expression by immunohistochemistry in 72 OSCCs. Multivariate analysis was conducted to examine their role in survival. </p><p> <strong>Results </strong></p><p> p-mTOR expression was observed in 46 (63.9%) cancers and PTEN expression was absent in 22 (30.6%). An adverse independent prognostic value for high p-mTOR expression was found (P = .043) as well as for advanced tumor stage (P = .010) in patients' overall survival (OS). For disease-free survival (DFS), only advanced tumor stage (P = .001) presented an adverse independent prognostic value. <strong></strong></p><p> <strong>Conclusions</strong></p><p>  The effect of p-mTOR in OS of OSCC suggests that this marker may serve as a reliable biological marker to identify high-risk subgroups and as a guide to therapy. Furthermore, the high expression of p-mTOR suggests that this protein may be a promising therapeutic target in OSCC. </p><hr><p></p><p> <strong>Source: </strong>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology </p><p><a href="http://www.oooojournal.net/article/S2212-4403(13)00050-3/abstract" target="_blank"><font color="#0000ff"> Full Text</font></a></p> 0 0 http://idai.ir/browse.php?a_code=A-10-32-1610&slc_lang=fa&sid=1 Luís Silva Monteiro 10031947532846007473 10031947532846007473 Yes Medicine and Oral Surgery Department, Dental Sciences Group – Health Sciences Research Centre, Higher Institute of Health Sciences (ISCSN), CESPU, Paredes, Portugal Maria Leonor Delqado 10031947532846007474 10031947532846007474 No Pathology Department, Higher School of Health of Vale do Sousa, CESPU, Paredes, Portugal Sara Ricardo 10031947532846007475 10031947532846007475 No Pathology Department, Higher School of Health of Vale do Sousa, CESPU, Paredes, Portugal Fernanda Garcez 10031947532846007476 10031947532846007476 No Pathology Department, Higher School of Health of Vale do Sousa, CESPU, Paredes, Portugal Barbas de Amaral 10031947532846007477 10031947532846007477 No Stomatology Department, Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal Saman Warnakulasuriya 10031947532846007478 10031947532846007478 No Oral Medicine and WHO Collaborating Centre for Oral Cancer, Department of Clinical and Diagnostic Sciences, King's College London Dental Institute, London, United Kingdom Carlos Lopes 10031947532846007479 10031947532846007479 No Molecular Pathology and Immunology Department, Institute of Biomedical Sciences Abel Salazar (ICBAS), Porto University, Porto, Portugal